Diacerein - Neopharmed Gentili
Alternative Names: Art 50; Artrodar; Artrolyt; Cartivix; Diacerhein; Diacetylrhein; Fisiodar; Galaxdar; KW 4800; Matrix; Rhein diacetate; SF 277; VerborilLatest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator Istituto Gentili; Proter
- Developer Abiogen Pharma; Ecupharma; Faran; Kyowa Kirin; Lacer; Myungmoon Pharm; Neo-Farmaceutica; Neopharmed Gentili; Proter; TRB Pharma; Wockhardt
- Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Caspase 1 inhibitors; Interleukin 1 beta inhibitors; NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Osteoarthritis
Most Recent Events
- 19 Nov 2024 Discontinued - Phase-III for Osteoarthritis in Canada (PO)
- 06 Sep 2022 No development reported - Phase-III for Osteoarthritis in Canada (PO) (NDR Batch 23)
- 27 Jul 2022 Lacer has been acquired by Italfarmaco